RAJNI KAUL, who was married to Mahendra Kaul of the BBC and was a talented and well-read broadcaster in her own right, died on Tuesday (31), aged 92, in Faridabad near Delhi.
Her death was announced in London by her circuit judge daughter, Her Honour Judge Kalyani Kaul QC, who said: “She died peacefully in her sleep, after having her lunch at the wonderful Golden Estate in Faridabad where she had been staying during Covid-19 to protect her health.”
Rajni was predeceased by her husband, who died, aged 95, in London, on July 11, 2018. The couple met when working for All India Radio in Delhi in the early days after independence. Rajni worked for AIR, then for the Voice of America in Washington, as did her husband, and finally for the Hindi service of the BBC after she and her husband came to the UK in 1961. They made London their home.
Rajni Kaul and her husband Mahendra pictured with the Queen.
Rajni was born in Peshawar on July 15, 1929, one of five children of Indernath and Sampiyari Kapur. After Partition in 1947, the family moved to Delhi where 17-year-old Rajni was recruited by AIR to sing songs in Punjabi and Pashto for a children’s programme and occasionally to read the news in Hindi.
It is there she met the Kashmiri Pandit, Mahendra Kaul, who was reading the news in Kashmiri and Urdu and producing drama. The couple married on May 2, 1955, and their daughter Kalyani was born in December 1960.
After the couple moved to Washington, Rajni qualified as a librarian. She had a love of books and considered it “heaven” when first ushered into a library. Her husband, meanwhile, worked for the Voice of America.
A new phase began when Rajni and Mahendra moved to London. While he pioneered TV programmes for newly-arrived Asian immigrants, Rajni specialised as a children’s librarian. She also worked for the BBC Hindi Service presenting a children’s programme, which was very popular in India. A generation of young people grew up with "Rajni didi" and she would get sackfuls of fan mail which she insisted on answering personally. She also presented a women’s programme.
Rajni assisted Mahendra when and launched tandoori chicken from the Gaylord restaurant in Mortimer Street near Broadcasting House in London. “He understands masala,” Rajni once said.
When Mahendra kept getting invitations from Downing Street, she joked: “Mahendra flirts with Margaret Thatcher – she loves it.”
Honour Judge Kalyani Kaul with her parents Rajni and Mahendra.
According to one anecdote, when Mrs Thatcher came down the the stairs at 10, Downing Street, Mahendra looked up at Britain’s first female prime minister and exclaimed: “Wow! You look beautiful.” “You think so?” she said.
Throughout her life, Rajni tried to maintain her love of reading with her motto: “A book a day.” She did not care for romantic fiction, though.
She would read when taking the bus to Bush House in the Aldwych and even when walking to work. She would tell of the tall Englishman she bumped into and who admonished her, “Look up.”
In an interview with a former BBC colleague, Pervaiz Alam, she said she wanted to depart on her final journey with probably three books - something by the black American author Toni Morrison (“I am willing to touch her feet"), a translation from Japanese literature and Michelle Obama’s Becoming.
Kalyani said: “Her greatest love was for her grandchildren Symran and Callum.”
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.